Strategic and Tactical Competitive Insights
We deliver crucial insights that empower clients to make winning strategic decisions.
Our consulting uncovers threats/opportunities, empowering clients to make strategic decisions that yield winning outcomes.
We deliver evidence-based recommendations, informed by expert interviews, to help clients address issues across:
- Asset Clinical Development and Commercialization
- R&D and Pipeline Assets
- Market Access
- Pricing/Reimbursement
- Regulatory Needs
- Emerging Markets
- Biosimilars/Generics
- OTC Offerings
- Digital Health
We provide decision support across the product lifecycle:
- New Product Planning
- Brand Planning
- Mature Product Planning
Our research capabilities are bolstered by in-house experts and a network spanning:
- Oncology/Hematology (solid/liquid tumors etc.)
- Gene and Cell Therapy / Rare Diseases (muscular dystrophy, ophthalmology, hemophilia etc.)
- Inflammatory and Autoimmune Diseases (including rheumatology, dermatology, allergy, MS etc.)
- Neurological Disorders (including epilepsy, Alzheimer’s, schizophrenia, PD etc.)
- Respiratory Disorders (including asthma, COPD, IPF, PAH etc.)
- Cardiovascular Disorders / Diabetes (including stroke, lipid disorders etc.)
- Infectious Diseases / Vaccines (including HIV, HCV, flu, MRSA, RSV etc.)
- Pain (including chronic pain, cancer-associated pain etc.)
- Blood Disorders (e.g. hemophilia)
With timely insights across therapy areas, we equip clients to accelerate competitive advantage.
Ready to build winning competitive strategies?
Let’s accelerate your success together. Contact us at info@lqventures.com.
November 18, 2025
Endocrinology Today—November 18, 2025
November 18, 2025
Lucid Diligence Brief: Johnson & Johnson acquires Halda Therapeutics
November 17, 2025
Oncology Today—November 17, 2025
November 17, 2025
Hematology Video Recap—November 17, 2025
November 17, 2025
Hematology Today—November 17, 2025
November 17, 2025
AI in Healthcare and Digital Health Today—November 17, 2025
November 17, 2025
Lucid Diligence Brief: ABL Bio and Eli Lilly Grabody-B license deal
November 16, 2025
Lucid Diligence Brief: Merck to acquire Cidara Therapeutics
November 14, 2025
Public Health Today—14 November, 2025
November 14, 2025